(Q38956597)

7 September 2017

title

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia (English)

1 reference

7 September 2017

1 reference

W Zeijlemaker

1

1 reference

7 September 2017

A Kelder

2

1 reference

7 September 2017

Y J M Oussoren-Brockhoff

3

1 reference

7 September 2017

W J Scholten

4

1 reference

7 September 2017

A N Snel

5

1 reference

7 September 2017

D Veldhuizen

6

1 reference

7 September 2017

J Cloos

7

1 reference

7 September 2017

G J Ossenkoppele

8

1 reference

7 September 2017

G J Schuurhuis

9

1 reference

7 September 2017

publication date

16 September 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

30

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

439-446

1 reference

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Stem cell gene expression programs influence clinical outcome in human leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Recent advances in acute myeloid leukemia stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

The origin and evolution of mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Cancer stem cell definitions and terminology: the devil is in the details.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

12 December 2020

Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells

1 reference

12 December 2020

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

1 reference

12 December 2020

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

12 December 2020

Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities

1 reference

12 December 2020

Absence of leukaemic CD34(+) cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

1 reference

12 December 2020

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

1 reference

12 December 2020

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

1 reference

12 December 2020

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

1 reference

12 December 2020

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia

1 reference

12 December 2020

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.252

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/LEU.2015.252

1 reference

Dimensions Publication ID

7 September 2017

1017804119

0 references

1 reference